安全性

经过长达八年在灵长类实验动物身上的毒理学安全性验证，该基因靶向编辑技术终于正式获批开展人体三期临床试验。

jīng guò zhǎng dá bā nián zài líng zhǎng lèi shí yàn dòng wù shēn shàng de dú lǐ xué ān quán xìng yàn zhèng, gāi jī yīn bǎ xiàng biān jí jì shù zhōng yú zhèng shì huò pī kāi zhǎn rén tǐ sān qī lín chuáng shì yàn.

After eight years of toxicological safety verification in primate experimental animals, this gene-targeted editing technology has finally been officially approved for human phase III clinical trials.